This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Toni Weinschenk
Chief Technology Officer at Immatics Biotechnologies


Chief Technology Officer

Toni Weinschenk co-founded Immatics Biotechnologies GmbH in 2000.

Over the past two decades, Toni Weinschenk has been active in the field of cancer immunology. He oversees all of Immatics’ target discovery and companion diagnostics activities..

He is the inventor of Immatics’ proprietary XPRESIDENT® technology platform, which is enabling the discovery and validation of the most comprehensive array of cancer targets derived from both, cell surface and intracellular antigens. Toni Weinschenk has earned the reputation as the world’s leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT®. Targets identified by XPRESIDENT® have proven to be important assets in several licensing deals with partners from the pharma industry and academia.

Toni Weinschenk is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Report.

Toni Weinschenk studied biochemistry at the University of Tuebingen, Germany and at the Max-Planck-Institute, Munich, Germany.

Agenda Sessions

  • T-cell Targets – Identification and Clinical Use